Comegna, M.; Terlizzi, V.; Salvatore, D.; Colangelo, C.; Di Lullo, A.M.; Zollo, I.; Taccetti, G.; Castaldo, G.; Amato, F.
Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype. Antibiotics 2021, 10, 828.
https://doi.org/10.3390/antibiotics10070828
AMA Style
Comegna M, Terlizzi V, Salvatore D, Colangelo C, Di Lullo AM, Zollo I, Taccetti G, Castaldo G, Amato F.
Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype. Antibiotics. 2021; 10(7):828.
https://doi.org/10.3390/antibiotics10070828
Chicago/Turabian Style
Comegna, Marika, Vito Terlizzi, Donatello Salvatore, Carmela Colangelo, Antonella Miriam Di Lullo, Immacolata Zollo, Giovanni Taccetti, Giuseppe Castaldo, and Felice Amato.
2021. "Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype" Antibiotics 10, no. 7: 828.
https://doi.org/10.3390/antibiotics10070828
APA Style
Comegna, M., Terlizzi, V., Salvatore, D., Colangelo, C., Di Lullo, A. M., Zollo, I., Taccetti, G., Castaldo, G., & Amato, F.
(2021). Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype. Antibiotics, 10(7), 828.
https://doi.org/10.3390/antibiotics10070828